Biodesix (NASDAQ:BDSX) is focused on developing diagnostic tests intended to improve patient outcomes by answering specific clinical questions, Chief Financial Officer Robin Cowie said at a Barclays ...

Affinity Technologies (NASDAQ:BIAF) announced on March 10, 2026, the launch of a large longitudinal clinical study involving 2,000 patients to evaluate the performance of its CyPath® Lung technology ...

A revolutionary AI-powered diagnostic test for chronic obstructive pulmonary disease (COPD) is set to be introduced in GP surgeries across England from 14 April, offering a faster and more accurate ...

Record CyPath® Lung Revenue and Unit Sales. Revenue from our noninvasive diagnostic for lung cancer increased 87% over 2024 with the number of tests performed rising 99% year over year, reflecting ...

Affinity Technologies, Inc. (NASDAQ:BIAF) released its financial results for the year ended December 31, 2025, according to a ...

With a San Antonio biotech firm’s test, your phlegm could help save you from cancer. The screening method developed by bioAffinity Technologies Inc. uses AI-aided computer analysis of a patient’s ...

A multicenter prospective study validated that an electronic nose (eNose) can accurately detect lung cancer in individuals with suspected disease. In the validation cohort, a new eNose model achieved ...

This story is sponsored by Utahradon.org. Almost everyone has an occasional cough or congestion and they write it off as no big deal, but if you live in Utah, it's critical to be aware that a bigger ...